David Kirn - Dec 15, 2022 Form 4 Insider Report for 4D Molecular Therapeutics, Inc. (FDMT)

Role: Chief Executive Officer, Director, 10%+ Owner
Signature: /s/ August J. Moretti, Attorney-in-Fact for David Kirn
Stock symbol: FDMT
Transactions as of: Dec 15, 2022
Transactions value $: -$2,018,344
Form type: 4
Date filed: 12/19/2022, 04:56 PM
Previous filing: Feb 3, 2022
Next filing: Jan 23, 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	FDMT	Common Stock	Sale	-$741K	-31.4K	-1.57%	$23.56	1.97M	Dec 15, 2022	Direct	F1, F2
transaction	FDMT	Common Stock	Sale	-$36.2K	-1.5K	-0.08%	$24.13	1.97M	Dec 15, 2022	Direct	F1, F3
transaction	FDMT	Common Stock	Sale	-$625K	-27.6K	-1.4%	$22.66	1.94M	Dec 16, 2022	Direct	F1, F4
transaction	FDMT	Common Stock	Sale	-$616K	-26.3K	-1.36%	$23.39	1.91M	Dec 16, 2022	Direct	F1, F5

Showing 1 to 4 of 4 entries

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.
F2	The transaction was executed in multiple trades in prices ranging from $23.04 to $24.04, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F3	The transaction was executed in multiple trades in prices ranging from $24.07 to $24.20, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F4	The transaction was executed in multiple trades in prices ranging from $22.18 to $23.18, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F5	The transaction was executed in multiple trades in prices ranging from $23.19 to $23.74, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Remarks:

Chief Executive Officer